2. Search Result
Search Result
Results for "

rat vas deferens

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

4

Peptides

2

Natural
Products

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-117040
    nor-Binaltorphimine
    5+ Cited Publications

    Norbinaltorphimine; NorBNI

    		 Opioid Receptor Neurological Disease
    nor-Binaltorphimine (Norbinaltorphimine; NorBNI) is a selective, long-acting competitive antagonist of the κ-opioid receptor. nor-Binaltorphimine blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. nor-Binaltorphimine suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. nor-Binaltorphimine is applicable to research related to neurological disorders such as pain .
    nor-Binaltorphimine
  • HY-101366
    A-61603

    		Adrenergic Receptor Endocrinology
    A-61603 is a selective α1A/α1a-adrenergic receptor agonist with Ki of 8.89 nM for rat submaxillary gland α1A, Ki of 30.5 nM for cloned bovine α1a. A-61603 potentiates Ca 2+ transients with EC50 of 6.9 nM. A-61603 stimulates phosphoinositide hydrolysis, induces contractile responses in vas deferens, prostate strips, and spleen strips, and exhibits low activity in aortic rings. A-61603 can be used for research on adrenergic function .
    A-61603
  • HY-P1317A
    Nociceptin (1-13), amide TFA

    		Opioid Receptor Neurological Disease
    Nociceptin (1-13), amide TFA is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
    Nociceptin (1-13), amide TFA
  • HY-P3679
    Neuropeptide Y (1-24) (human)

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide Y (1-24) (human) is a neuropeptide with potencies in inhibiting the electricity stimulated twitch response of rat vas deferens. Neuropeptide Y (1-24) (human) stimulates N-methyl-D-aspartate (NMDA)-induced neuronal activation in the rat CA3 region of the dorsal hippocampus in vivo .
    Neuropeptide Y (1-24) (human)
  • HY-116680
    LY53857

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
    LY53857
  • HY-W982195
    Napamezole hydrochloride

    		Adrenergic Receptor 5-HT Receptor Neurological Disease
    Napamezole hydrochloride is an orally active α-2 adrenergic receptor antagonist and serotonin (5-HT Receptor) reuptake inhibitor, with Ki values of 28 nM and 93 nM for rat α-2 and α-1 adrenergic receptors, respectively. Napamezole hydrochloride can be used for the research of depression .
    Napamezole hydrochloride
  • HY-P1317
    Nociceptin (1-13), amide

    		Opioid Receptor Neurological Disease
    Nociceptin (1-13)，amide is a potent ORL1 receptor (opioid receptor-like 1 receptor，OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
    Nociceptin (1-13), amide
  • HY-160932
    RS-15385-198

    		Adrenergic Receptor Endocrinology
    RS-15385-198 is the enantiomer of Delequamine (RS-15385-197) (HY-106874). RS-15385-198 exhibits a pKi of 6.32 for α2-adrenoceptors in the rat cortex. RS-15385-198 is an antagonist for UK-14304 (HY-B0659) in the rat vas deferens and in the guinea-pig ileum .
    RS-15385-198
  • HY-110016
    Docosatetraenylethanolamide

    DEA

    		 Endogenous Metabolite Cannabinoid Receptor Neurological Disease
    Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a Ki value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .
    Docosatetraenylethanolamide
  • HY-108985
    Trazium esilate

    EGYT-3615

    		 Others Neurological Disease
    Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat .
    Trazium esilate
  • HY-106388A
    Fadolmidine hydrochloride

    		Adrenergic Receptor Neurological Disease
    Fadolmidine hydrochloride is a novel, selective α2-adrenoceptor (α2-AR) agonist with EC50 values of 0.4 nM, 4.9 nM and 0.5 nM for 2A, 2B and 2C, respectively. Fadolmidine hydrochloride has been effective against various submodalities of pain such as heat pain, mechanical pain, and visceral pain. Fadolmidine hydrochloride inhibits also electrically evoked contractions in rat vas deferens .
    Fadolmidine hydrochloride
  • HY-P2601A
    Tyr-α-CGRP (human) TFA

    		CGRP Receptor Others
    Tyr-α-CGRP (human) TFA is an N-terminally extended human α-CGRP analog. Tyr-α-CGRP (human) TFA can bind to membrane preparations from rat brain and spleen with IC50 values of 0.2 nM and 0.5 nM, respectively, and induce positive chronotropic and inotropic effects in isolated guinea pig right and left atria with EC50 values of 282 nM and 74 nM, respectively. Tyr-α-CGRP (human) TFA also inhibits contractile responses in rat vas deferens with an EC50 value of 1.9 nM .
    Tyr-α-CGRP (human) TFA
  • HY-167689
    Parethoxycaine hydrochloride

    		Adrenergic Receptor Neurological Disease
    Parethoxycaine hydrochloride is an anesthetic with nerve conduction blocking activity. Parethoxycaine hydrochloride exhibits non-selective inhibitory effects on responses to various stimulants in rat vas deferens and guinea pig ileum muscles. Parethoxycaine hydrochloride has an enhanced effect on the action of norepinephrine, and its methyl bromide derivative also exhibits the same properties on the action of norepinephrine and potassium ions. Derivatives of parethoxycaine hydrochloride have significant effects on calcium dose-response curves, displaying different tissue and stimulant selectivities. The mechanism of action of Parethoxycaine hydrochloride involves the regulation of calcium transport processes .
    Parethoxycaine hydrochloride
  • HY-136693
    L-654284

    		Adrenergic Receptor Neurological Disease
    L-654284 is an α2-adrenergic receptor antagonist with significant selectivity. L-654284 competes with the binding of 3H-clonidine and 3H-rauwolscine in vitro and shows Ki values of 0.8 nM and 1.1 nM, respectively. L-654284 can block the protrusion effect of clonidine in isolated vas deferens in rats, with a pA2 value of 9.1. L-654284 exhibits remarkable selectivity for α2 and α1 adrenergic receptors, and exhibits a Ki of 110 nM in inhibiting 3H-prazosin binding. L-654284 can significantly increase the turnover rate of norepinephrine in rat cerebral cortex in vivo, showing α2-adrenergic receptor blocking activity in the central nervous system .
    L-654284
  • HY-W412336
    Acid blue 129

    		Biochemical Assay Reagents P2Y Receptor Others
    Acid blue 129 is an acidic dye and highly selective antagonist at the P2Y-receptor of the guinea pig taenia coli. Acid blue 129 does not show any effect at the P2X-receptor of the rat vas deferens. Acid blue 129 can be used for the dyeing of cotton, wool, silk, nylon, paper and leather .
    Acid blue 129
  • HY-106388
    Fadolmidine

    		Adrenergic Receptor Neurological Disease
    Fadolmidine is a novel, selective α2-adrenoceptor (α2-AR) agonist with EC50 values of 0.4 nM, 4.9 nM and 0.5 nM for 2A, 2B and 2C, respectively. Fadolmidine has been effective against various submodalities of pain such as heat pain, mechanical pain, and visceral pain. Fadolmidine inhibits also electrically evoked contractions in rat vas deferens .
    Fadolmidine
  • HY-N9554
    WIN-64821

    		Neurokinin Receptor Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology
    WIN-64821 is a secondary metabolite produced by Aspergillus species, and acts as a Neurokinin Receptor antagonist. The Ki values of WIN-64821 for NK1, NK2 and NK3 receptors are 0.24 (human astrocytoma cells), 0.26 (rat duodenum) and 15.2 (guinea pig forebrain) μM, respectively. WIN-64821 inhibits apamin-induced contraction of rat vas deferens, blocks substance P-induced contraction of guinea pig ileum and Ca 2+ efflux in human astrocytoma cells. WIN-64821 is applicable to analgesic and anti-inflammatory research .
    WIN-64821
  • HY-182563
    Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide

    		Opioid Receptor Endocrinology
    Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide is a μ/δ opioid receptor ligand with high μ opioid receptor selectivity and agonist activity. Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide has an IC50 of 237 nM for μ receptors and 1050 nM for δ receptors. Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide shows Ki values of 17 nM for μ receptors and 480 nM for δ receptors. Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide inhibits electrically evoked contractions of guinea pig ileum and mouse vas deferens. Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide serves as a starting compound for structure-activity relationship investigations of μ receptor recognition .
    Tyr-Ala-N-(1,3-dimethylbutyl)glycinamide
  • HY-183921
    SQ 32547

    		Calcium Channel Cardiovascular Disease Inflammation/Immunology
    SQ 32547 is a dihydropyridine calcium channel inhibitor with antihypertensive and anti-ischemic activities. SQ 32547 modulates sarcolemmal voltage-dependent calcium channels to inhibit calcium influx, and exerts direct anti-ischemic activity by suppressing myocardial contracture formation and reducing lactate dehydrogenase (LDH) release. SQ 32547 can be used in research related to hypertension, angina pectoris and neurogenic inflammation .
    SQ 32547

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: